Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 245

1.

Targeting p19 in psoriatic arthritis: more than just another therapeutic approach?

Kerschbaumer A, Aletaha D.

Lancet. 2020 Apr 4;395(10230):1091-1093. doi: 10.1016/S0140-6736(20)30525-0. Epub 2020 Mar 13. No abstract available.

PMID:
32178770
2.

Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal?

Studenic P, Felson D, de Wit M, Alasti F, Stamm TA, Smolen JS, Aletaha D.

Ann Rheum Dis. 2020 Apr;79(4):445-452. doi: 10.1136/annrheumdis-2019-216529. Epub 2020 Feb 5.

PMID:
32024651
3.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.

Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, McInnes IB, Sepriano A, van Vollenhoven RF, de Wit M, Aletaha D, Aringer M, Askling J, Balsa A, Boers M, den Broeder AA, Buch MH, Buttgereit F, Caporali R, Cardiel MH, De Cock D, Codreanu C, Cutolo M, Edwards CJ, van Eijk-Hustings Y, Emery P, Finckh A, Gossec L, Gottenberg JE, Hetland ML, Huizinga TWJ, Koloumas M, Li Z, Mariette X, Müller-Ladner U, Mysler EF, da Silva JAP, Poór G, Pope JE, Rubbert-Roth A, Ruyssen-Witrand A, Saag KG, Strangfeld A, Takeuchi T, Voshaar M, Westhovens R, van der Heijde D.

Ann Rheum Dis. 2020 Jan 22. pii: annrheumdis-2019-216655. doi: 10.1136/annrheumdis-2019-216655. [Epub ahead of print]

4.

Histone deacetylase 1 (HDAC1): A key player of T cell-mediated arthritis.

Göschl L, Preglej T, Boucheron N, Saferding V, Müller L, Platzer A, Hirahara K, Shih HY, Backlund J, Matthias P, Niederreiter B, Hladik A, Kugler M, Gualdoni GA, Scheinecker C, Knapp S, Seiser C, Holmdahl R, Tillmann K, Plasenzotti R, Podesser B, Aletaha D, Smolen JS, Karonitsch T, Steiner G, Ellmeier W, Bonelli M.

J Autoimmun. 2020 Mar;108:102379. doi: 10.1016/j.jaut.2019.102379. Epub 2019 Dec 26.

PMID:
31883829
5.

Pseudoerosions of Hands and Feet in Rheumatoid Arthritis: Anatomic Concepts and Redefinition.

Hirtler L, Rath C, Platzgummer H, Aletaha D, Kainberger F.

J Clin Med. 2019 Dec 9;8(12). pii: E2174. doi: 10.3390/jcm8122174.

6.

A critical review of the reproductive safety of Leflunomide.

Pfaller B, Pupco A, Leibson T, Aletaha D, Ito S.

Clin Rheumatol. 2020 Feb;39(2):607-612. doi: 10.1007/s10067-019-04819-4. Epub 2019 Nov 22. Review.

PMID:
31758422
7.

An updated matrix to predict rapid radiographic progression of early rheumatoid arthritis patients: pooled analyses from several databases.

Vanier A, Smolen JS, Allaart CF, Vollenhoven RV, Verschueren P, Vastesaeger N, Saevarsdottir S, Visser K, Aletaha D, Combe B, Fautrel B.

Rheumatology (Oxford). 2019 Nov 13. pii: kez542. doi: 10.1093/rheumatology/kez542. [Epub ahead of print]

PMID:
31722413
8.

Disease activity improvements with optimal discriminatory ability between treatment arms: applicability in early and established rheumatoid arthritis clinical trials.

Smolen J, Fleischmann R, Aletaha D, Li Y, Zhou Y, Sainsbury I, Galindo IL.

Arthritis Res Ther. 2019 Nov 10;21(1):231. doi: 10.1186/s13075-019-2005-9.

9.

Synovitis in rheumatoid arthritis detected by grey scale ultrasound predicts the development of erosions over the next three years.

Möller B, Aletaha D, Andor M, Atkinson A, Aubry-Rozier B, Brulhart L, Dan D, Finckh A, Grobéty V, Mandl P, Micheroli R, Nissen MJ, Nydegger AM, Scherer A, Tamborrini G, Ziswiler HR, Zufferey P.

Rheumatology (Oxford). 2019 Oct 19. pii: kez460. doi: 10.1093/rheumatology/kez460. [Epub ahead of print]

10.

The slippery road of adherence in chronically ill individuals.

Studenic P, Aletaha D.

Rheumatology (Oxford). 2020 Jan 1;59(1):9-11. doi: 10.1093/rheumatology/kez495. No abstract available.

PMID:
31630174
11.

Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission.

Aletaha D, Wang X, Zhong S, Florentinus S, Monastiriakos K, Smolen JS.

Semin Arthritis Rheum. 2020 Apr;50(2):276-284. doi: 10.1016/j.semarthrit.2019.09.005. Epub 2019 Sep 19.

PMID:
31590930
12.

Treating Rheumatic Diseases to Target: A Story of Success.

Aletaha D.

Rheum Dis Clin North Am. 2019 Nov;45(4):xi-xii. doi: 10.1016/j.rdc.2019.08.002. Epub 2019 Aug 22. No abstract available.

PMID:
31564301
13.

The role of ultrasound and magnetic resonance imaging for treat to target in rheumatoid arthritis and psoriatic arthritis.

Mandl P, Aletaha D.

Rheumatology (Oxford). 2019 Dec 1;58(12):2091-2098. doi: 10.1093/rheumatology/kez397.

PMID:
31518423
14.

Rheumatoid arthritis disease activity and the risk of aseptic arthroplasty loosening.

Böhler C, Weimann P, Alasti F, Smolen JS, Windhager R, Aletaha D.

Semin Arthritis Rheum. 2020 Apr;50(2):245-251. doi: 10.1016/j.semarthrit.2019.07.011. Epub 2019 Aug 1.

PMID:
31471012
15.

Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis.

Aletaha D, Maa JF, Chen S, Park SH, Nicholls D, Florentinus S, Furtner D, Smolen JS.

Ann Rheum Dis. 2019 Dec;78(12):1609-1615. doi: 10.1136/annrheumdis-2018-214918. Epub 2019 Aug 21.

16.

Remission in rheumatoid arthritis: missing objectives by using inadequate DAS28 targets.

Aletaha D, Smolen JS.

Nat Rev Rheumatol. 2019 Nov;15(11):633-634. doi: 10.1038/s41584-019-0279-6. Review. No abstract available.

PMID:
31427763
17.

Analysis of gene expression in rheumatoid arthritis and related conditions offers insights into sex-bias, gene biotypes and co-expression patterns.

Platzer A, Nussbaumer T, Karonitsch T, Smolen JS, Aletaha D.

PLoS One. 2019 Jul 25;14(7):e0219698. doi: 10.1371/journal.pone.0219698. eCollection 2019.

18.

Predictors of successful discontinuation of biologic and targeted synthetic DMARDs in patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review.

Schlager L, Loiskandl M, Aletaha D, Radner H.

Rheumatology (Oxford). 2020 Feb 1;59(2):324-334. doi: 10.1093/rheumatology/kez278.

PMID:
31325305
19.

Does Triple Conventional Synthetic Disease-Modifying Antirheumatic Drug Therapy Improve upon Methotrexate as the Initial Treatment of Choice for a Rheumatoid Arthritis Patient?

Aletaha D, Smolen JS.

Rheum Dis Clin North Am. 2019 Aug;45(3):315-324. doi: 10.1016/j.rdc.2019.04.002. Epub 2019 Jun 5. Review.

PMID:
31277746
20.

Disease activity assessment in patients with psoriatic arthritis.

Kerschbaumer A, Smolen JS, Aletaha D.

Best Pract Res Clin Rheumatol. 2018 Jun;32(3):401-414. doi: 10.1016/j.berh.2018.08.004. Epub 2018 Oct 11. Review.

PMID:
31171311
21.

Risk of Developing Additional Immune-Mediated Manifestations: A Retrospective Matched Cohort Study.

Aletaha D, Epstein AJ, Skup M, Zueger P, Garg V, Panaccione R.

Adv Ther. 2019 Jul;36(7):1672-1683. doi: 10.1007/s12325-019-00964-z. Epub 2019 May 17.

22.

Risk profiling for a refractory course of rheumatoid arthritis.

Bécède M, Alasti F, Gessl I, Haupt L, Kerschbaumer A, Landesmann U, Loiskandl M, Supp GM, Smolen JS, Aletaha D.

Semin Arthritis Rheum. 2019 Oct;49(2):211-217. doi: 10.1016/j.semarthrit.2019.02.004. Epub 2019 Feb 8.

23.

Achieving Clinical Remission for Patients With Rheumatoid Arthritis.

Aletaha D, Smolen JS.

JAMA. 2019 Feb 5;321(5):457-458. doi: 10.1001/jama.2018.21249. No abstract available.

PMID:
30721278
24.

Workforce requirements in rheumatology: a systematic literature review informing the development of a workforce prediction risk of bias tool and the EULAR points to consider.

Unger J, Putrik P, Buttgereit F, Aletaha D, Bianchi G, Bijlsma JWJ, Boonen A, Cikes N, Dias JM, Falzon L, Finckh A, Gossec L, Kvien TK, Matteson EL, Sivera F, Stamm TA, Szekanecz Z, Wiek D, Zink A, Dejaco C, Ramiro S.

RMD Open. 2018 Dec 5;4(2):e000756. doi: 10.1136/rmdopen-2018-000756. eCollection 2018.

25.

EULAR 'points to consider' for the conduction of workforce requirement studies in rheumatology.

Dejaco C, Putrik P, Unger J, Aletaha D, Bianchi G, Bijlsma JW, Boonen A, Cikes N, Finckh A, Gossec L, Kvien TK, Madruga Dias J, Matteson EL, Sivera F, Stamm TA, Szekanecz Z, Wiek D, Zink A, Ramiro S, Buttgereit F.

RMD Open. 2018 Dec 5;4(2):e000780. doi: 10.1136/rmdopen-2018-000780. eCollection 2018.

26.

Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity.

Landewé R, Ritchlin CT, Aletaha D, Zhang Y, Ganz F, Hojnik M, Coates LC.

Rheumatology (Oxford). 2019 Jun 1;58(6):1025-1033. doi: 10.1093/rheumatology/key417.

27.

Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study.

Norvang V, Sexton J, Kristianslund EK, Olsen IC, Uhlig T, Bakland G, Krøll F, Rødevand E, Wierød A, Kvien TK, Smolen JS, Aletaha D, Haavardsholm EA.

RMD Open. 2018 Oct 26;4(2):e000773. doi: 10.1136/rmdopen-2018-000773. eCollection 2018.

28.

Diagnosis and Management of Rheumatoid Arthritis: A Review.

Aletaha D, Smolen JS.

JAMA. 2018 Oct 2;320(13):1360-1372. doi: 10.1001/jama.2018.13103. Review.

PMID:
30285183
29.

Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for PSoriatic Arthritis (DAPSA) based on 28 joints?

Michelsen B, Sexton J, Smolen JS, Aletaha D, Krogh NS, van der Heijde D, Kvien TK, Hetland ML.

Ann Rheum Dis. 2018 Dec;77(12):1736-1741. doi: 10.1136/annrheumdis-2018-213463. Epub 2018 Sep 20.

PMID:
30237203
30.

Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey.

Roodenrijs NMT, de Hair MJH, van der Goes MC, Jacobs JWG, Welsing PMJ, van der Heijde D, Aletaha D, Dougados M, Hyrich KL, McInnes IB, Mueller-Ladner U, Senolt L, Szekanecz Z, van Laar JM, Nagy G; whole EULAR Task Force on development of EULAR recommendations for the comprehensive management of difficult-to-treat rheumatoid arthritis.

Ann Rheum Dis. 2018 Dec;77(12):1705-1709. doi: 10.1136/annrheumdis-2018-213687. Epub 2018 Sep 7.

PMID:
30194273
31.

Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial.

Stamm TA, Machold KP, Aletaha D, Alasti F, Lipsky P, Pisetsky D, Landewe R, van der Heijde D, Sepriano A, Aringer M, Boumpas D, Burmester G, Cutolo M, Ebner W, Graninger W, Huizinga T, Schett G, Schulze-Koops H, Tak PP, Martin-Mola E, Breedveld F, Smolen J.

Arthritis Res Ther. 2018 Aug 9;20(1):174. doi: 10.1186/s13075-018-1667-z.

32.

Predictors for influenza vaccine acceptance among patients with inflammatory rheumatic diseases.

Harrison N, Poeppl W, Miksch M, Machold K, Kiener H, Aletaha D, Smolen JS, Forstner C, Burgmann H, Lagler H.

Vaccine. 2018 Aug 6;36(32 Pt B):4875-4879. doi: 10.1016/j.vaccine.2018.06.065. Epub 2018 Jul 3.

PMID:
29980390
33.

Are we failing patients in our assessment of treatment failure?

Nikiphorou E, Aletaha D, Bukhari M.

Rheumatology (Oxford). 2019 Apr 1;58(4):561-562. doi: 10.1093/rheumatology/key107. No abstract available.

PMID:
29897585
34.

To DAPSA or not to DAPSA? That is not the question.

Schoels MM, Smolen JS, Aletaha D.

Ann Rheum Dis. 2019 Jul;78(7):e61. doi: 10.1136/annrheumdis-2018-213548. Epub 2018 May 5. No abstract available.

PMID:
29730635
35.

Missing pebble in the mosaic of rheumatic diseases and mental health: younger does not always mean happier.

Alunno A, Studenic P, Wiek D, Balážová P, Aletaha D.

Ann Rheum Dis. 2019 Jun;78(6):e54. doi: 10.1136/annrheumdis-2018-213611. Epub 2018 Apr 28. No abstract available.

PMID:
29705744
36.

Early response to therapy predicts 6-month and 1-year disease activity outcomes in psoriatic arthritis patients.

Schoels MM, Landesmann U, Alasti F, Baker D, Smolen JS, Aletaha D.

Rheumatology (Oxford). 2018 Jun 1;57(6):969-976. doi: 10.1093/rheumatology/key004.

PMID:
29481661
37.

Tofacitinib for Psoriatic Arthritis.

Aletaha D, Kerschbaumer A, Smolen JS.

N Engl J Med. 2018 Feb 22;378(8):775. doi: 10.1056/NEJMc1715189. No abstract available.

PMID:
29469555
38.

Rheumatoid arthritis.

Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, Kavanaugh A, McInnes IB, Solomon DH, Strand V, Yamamoto K.

Nat Rev Dis Primers. 2018 Feb 8;4:18001. doi: 10.1038/nrdp.2018.1. Review.

PMID:
29417936
39.

The effects of structural damage on functional disability in psoriatic arthritis.

Kerschbaumer A, Baker D, Smolen JS, Aletaha D.

Ann Rheum Dis. 2017 Dec;76(12):2038-2045. doi: 10.1136/annrheumdis-2017-211433. Epub 2017 Aug 23.

PMID:
28835465
40.

Clinical and economic analysis of outcomes of dose tapering or withdrawal of tumor necrosis factor-α inhibitors upon achieving stable disease activity in rheumatoid arthritis patients.

Aletaha D, Snedecor SJ, Ektare V, Xue M, Bao Y, Garg V.

Clinicoecon Outcomes Res. 2017 Jul 28;9:451-458. doi: 10.2147/CEOR.S136327. eCollection 2017.

41.

Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force.

Smolen JS, Schöls M, Braun J, Dougados M, FitzGerald O, Gladman DD, Kavanaugh A, Landewé R, Mease P, Sieper J, Stamm T, Wit M, Aletaha D, Baraliakos X, Betteridge N, Bosch FVD, Coates LC, Emery P, Gensler LS, Gossec L, Helliwell P, Jongkees M, Kvien TK, Inman RD, McInnes IB, Maccarone M, Machado PM, Molto A, Ogdie A, Poddubnyy D, Ritchlin C, Rudwaleit M, Tanew A, Thio B, Veale D, Vlam K, van der Heijde D.

Ann Rheum Dis. 2018 Jan;77(1):3-17. doi: 10.1136/annrheumdis-2017-211734. Epub 2017 Jul 6. Erratum in: Ann Rheum Dis. 2018 Mar;77(3):472.

42.

Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition.

Schoels M, Alasti F, Smolen JS, Aletaha D.

Arthritis Res Ther. 2017 Jul 4;19(1):155. doi: 10.1186/s13075-017-1346-5.

43.

Clinical meaning and implications of serum hemoglobin levels in patients with rheumatoid arthritis.

Padjen I, Öhler L, Studenic P, Woodworth T, Smolen J, Aletaha D.

Semin Arthritis Rheum. 2017 Oct;47(2):193-198. doi: 10.1016/j.semarthrit.2017.03.001. Epub 2017 Mar 8.

PMID:
28385457
44.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.

Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poór G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D.

Ann Rheum Dis. 2017 Jun;76(6):960-977. doi: 10.1136/annrheumdis-2016-210715. Epub 2017 Mar 6. Review.

45.

Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.

Aletaha D, Bingham CO 3rd, Tanaka Y, Agarwal P, Kurrasch R, Tak PP, Popik S.

Lancet. 2017 Mar 25;389(10075):1206-1217. doi: 10.1016/S0140-6736(17)30401-4. Epub 2017 Feb 16. Erratum in: Lancet. 2017 May 20;389(10083):1980.

PMID:
28215362
46.

[Rheumatoid arthritis].

Aletaha D, Kerschbaumer A.

Z Rheumatol. 2017 Feb;76(1):8-14. doi: 10.1007/s00393-016-0251-7. Review. German.

PMID:
28058499
47.

EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis.

van Steenbergen HW, Aletaha D, Beaart-van de Voorde LJ, Brouwer E, Codreanu C, Combe B, Fonseca JE, Hetland ML, Humby F, Kvien TK, Niedermann K, Nuño L, Oliver S, Rantapää-Dahlqvist S, Raza K, van Schaardenburg D, Schett G, De Smet L, Szücs G, Vencovský J, Wiland P, de Wit M, Landewé RL, van der Helm-van Mil AH.

Ann Rheum Dis. 2017 Mar;76(3):491-496. doi: 10.1136/annrheumdis-2016-209846. Epub 2016 Oct 6.

PMID:
27991858
48.

2016 update of the EULAR recommendations for the management of early arthritis.

Combe B, Landewe R, Daien CI, Hua C, Aletaha D, Álvaro-Gracia JM, Bakkers M, Brodin N, Burmester GR, Codreanu C, Conway R, Dougados M, Emery P, Ferraccioli G, Fonseca J, Raza K, Silva-Fernández L, Smolen JS, Skingle D, Szekanecz Z, Kvien TK, van der Helm-van Mil A, van Vollenhoven R.

Ann Rheum Dis. 2017 Jun;76(6):948-959. doi: 10.1136/annrheumdis-2016-210602. Epub 2016 Dec 15.

49.

The EULAR points to consider for health professionals undertaking musculoskeletal ultrasound for rheumatic and musculoskeletal diseases.

Siddle HJ, Mandl P, Aletaha D, Vliet Vlieland TP, Backhaus M, Cornell P, D'Agostino MA, Ellegaard K, Iagnocco A, Jakobsen B, Jasinski T, Kildal NH, Lehner M, Möller I, Supp GM, O'Connor P, Redmond AC, Naredo E, Wakefield RJ.

Ann Rheum Dis. 2018 Feb;77(2):311-313. doi: 10.1136/annrheumdis-2016-210741. Epub 2016 Dec 9. No abstract available.

PMID:
27941130
50.

Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria.

Smolen JS, Aletaha D, Gruben D, Zwillich SH, Krishnaswami S, Mebus C.

Arthritis Rheumatol. 2017 Apr;69(4):728-734. doi: 10.1002/art.39996. Epub 2017 Mar 8.

Supplemental Content

Loading ...
Support Center